Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0033036 (
APC
)
10,214
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We examined if sevoflurane given before cold ischemia of intact hearts (anesthetic preconditioning,
APC
) affords additional protection by further improving mitochondrial energy balance and if this is abolished by a mitochondrial KATP blocker.
NADH
and FAD fluorescence was measured within the left ventricular wall of 5 groups of isolated guinea pig hearts: (1) hypothermia alone; (2) hypothermia+ischemia; (3)
APC
(4.1% sevoflurane)+cold ischemia; (4) 5-HD+cold ischemia, and (5) APC+5-HD+cold ischemia. Hearts were exposed to sevoflurane for 15 minutes followed by 15 minutes of washout at 37 degrees C before cooling, 2 hours of 27 degrees C ischemia, and 2 hours of 37 degrees C reperfusion. The KATP channel inhibitor 5-HD was perfused before and after sevoflurane. Ischemia caused a rapid increase in
NADH
and a decrease in FAD that waned over 2 hours. Warm reperfusion led to a decrease in
NADH
and an increase in FAD.
APC
attenuated the changes in
NADH
and FAD and further improved postischemic function and reduced infarct size. 5-HD blocked the cardioprotective effects of
APC
but not
APC
-induced alterations of
NADH
and FAD. Thus,
APC
improves redox balance and has additive cardioprotective effects with mild hypothermic ischemia. 5-HD blocks
APC
-induced cardioprotective effects but not improvements in mitochondrial bioenergetics. This suggests that mediation of protection by KATP channel opening during cold ischemia and reperfusion is downstream from the
APC
-induced improvement in redox state or that these changes in redox state are not attenuated by KATP channel antagonism.
...
PMID:Improved mitochondrial bioenergetics by anesthetic preconditioning during and after 2 hours of 27 degrees C ischemia in isolated hearts. 1611 32